

Tamar Peretz-Yablonski

Radiation and Medical Oncologist
Sharett Oncology Institute-**Hadassah-Hebrew University Medical Center**
Professor-The Hebrew University of Jerusalem
Lawrence Schact Chair of Oncology
Immediate Former Director, Sharett Oncology Institute

List of Publications

February 2022

Original Papers in Peer-Reviewed Journals

1. Klin B, **Peretz T**, Catane R, Olchwang D, and Magora F (1984). [Epidural morphine analgesia](#). Harefuah. 106:70-71.
2. Pfeffer R, Sulkes A, **Peretz T**, Fuks Z, and Catane R (1984). [Phase I study of the combination of Mitomycin and oral Metronidazol](#). Cancer Treatment Reports. 68: (9), 1191-1192.
3. **Yablonski-Peretz T** and Durst A L (1984). [Intra-arterial chemotherapy for the treatment of liver metastases using an implantable pump](#). Harefuah. 107: 101-102.
4. **Peretz T**, Klin B, Warner E, Olchwang D, and Catane R (1985). [Continuous epidural narcotic analgesia for intractable pain due to malignancy](#). J Surg. Oncol. 29:8-10.
5. Isacson, R, **Yablonski-Peretz T**, Uzieli B, Sulkes A and Biran S (1985). [High dose folinic acid and 5-fluorouracil in gastrointestinal malignancies](#). Int. J. Mediterranean Soc. Chem. Supp. to: 4:1153-1156.
6. Gez E, Sulkes A, **Yablonski-Peretz T**, and Weshler Z (1986). [Combined 5-Fluorouracil \(5FU\) and radiation therapy following resection of locally advanced gastric carcinoma](#). J. Surg. Oncol. 31: 139-142.
7. Gorodetsky R, Fuks Z, **Peretz T**, and Ginsburg H (1986). [Direct fluorometric determination of erythrocyte free and zinc protoporphyrins in health and disease](#). J. Clin. Biochem. 18: 362-368.
8. **Peretz T**, Beller U, Horowitz A, Biran S, and Anteby SU (1986). [The influence of sex hormones on ovarian carcinoma cell line in tissue culture](#). Harefuah. 111: 1-3.

9. Gorodetsky R, Fuks Z, **Peretz T**, and Ginsburg H (1986). [Elevation of erythrocyte zinc and free protoporphyrins in cancer patients with metastatic spread](#). Euro. J. Cancer Clin. Oncol. 22: 1515-1521.
10. Libson E, Bloom RA, Halpern I, **Peretz T**, Husband JE (1987). [Mediastinal lymph node metastases from gastrointestinal carcinomas](#). Cancer. 59(8) 1490-1493.
11. Gez E, Sulkes A, **Peretz T**, and Weshler Z(1988). [Combined 5-Fluorouracil and radiation therapy following resection of locally advanced gastric carcinoma: a 5 years follow-up](#). Recent Results in Cancer Research. 110: 52-56.
12. **Peretz T**, Freund HR, Isacson R, Ben-Yosef A, Goldin E, Haskel L, Chisin R, Biran S, and Durst AL (1988). [Treatment of primary and metastatic liver cancer using an implantable chemoinfusion pump](#). Isr. J. Med. Sci. 24: 562-567.
13. Warner-Efrati E, Sulkes A, Weshler Z, **Peretz T**, Ben-Yosef R, Catane R, and Biran S (1988). [Chemotherapy induction, consolidation radiotherapy and maintenance alternating chemotherapy in small cell carcinoma of the lung](#). Isr. J. Med. Sci. 24: 593-598.
14. **Peretz T**, Nori D, Hilaris B, Osian A, Linares L, and Anderson L (1988). [CT guided transperineal implants in pelvic tumors](#). 8th Brachytherapy Update. 179-192.
15. Baider L, **Peretz T**, and Kaplan De-Nour A (1989). [Gender and adjustment to chronic disease: a study of couples with colon cancer](#). General Hospital Psy. 11: 1-8.
16. **Peretz T**, Nori D, Hilaris B, Manolatos S, Linares L, Harrison L, Anderson LL, Fuks Z, and Brennan MF (1989). [Treatment of primary unresectable carcinoma of the pancreas with I¹²⁵ implantation](#). Int. J. Radiat. Oncol. Biol. Phys. 17: 931-935.
17. Uzieli B, **Peretz T**, Sulkes A, Feigin E, Isacson R, and Biran S (1989). [Cisplatin, Bleomycin and Methotrexate \(PBM\) chemotherapy in locally advanced and metastatic head and neck cancer](#). J. Surg. Oncol. 42: (4) 234-237.
18. Nori D, Bains M, Hilaris BS, Harrison L, Fass D, **Peretz T**, Donath D, and Fuks Z (1989). [New intraoperative brachytherapy techniques for positive or close surgical margins](#). J. Surg. Oncol. 42: (4) 54-57.

19. Gabizon A, **Peretz T**, Sulkes A, Amselem S, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S, and Barenholz Y (1989). [Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study](#). Eur. J. Cancer Clin Oncol. 25: 1795-1803.
20. Gabizon AA, **Peretz T**, Sulkes A, Cohen D, Goren D, Amselem S, Fromer I, Chisin R, and Barenholz Y (1990). [Preclinical and clinical experience with a doxorubicin-liposome preparation](#). J. of Liposome Research. 1(4): 491-502.
21. **Peretz T**, Anteby SU, Beller U, Horowitz AT, Fuks Z, and Vlodavsky I (1990). [Maintenance on extracellular matrix and expression of heparanase activity by human ovarian carcinoma cells from biopsy specimens](#). International Journal of Cancer. 45:1054-1060.
22. Meijer S, **Peretz T**, Gaynor J, Tan C, Hajdu SI, and Brennan MF (1990). [Primary colorectal sarcoma: a retrospective review and prognostic factor study of 50 consecutive patients](#). Archives of Surgery. 125: 1163-1168.
23. Mandell L, Ghavimi F, **Peretz T**, LaQuaglia M, and Exelby P (1990). [Radiocurability of Microscopic Disease in Childhood Rhabdomyosarcoma with radiation doses less than 4,000 cGy](#). Journal of Clinical Oncology. 8: (9), 1536-1542.
24. Gabizon A, Chisin R, Amselem S, Druckman S, Cohen R, Goren D, Fromer I, **Peretz T**, Sulkes A, and Barenholz Y (1991). [Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin](#). British Journal of Cancer. 64: 1125-1132.
25. Baider L, **Peretz T**, and Kaplan De-Nour A (1993). [Effect of the holocaust on cancer patients: a comparative study](#). Psychiatry: Interpersonal and Biological Processes. 56: 349-355.
26. Baider L, **Peretz T**, and Kaplan De-Nour A (1992). [Effect of the holocaust on coping with cancer](#). Soc. Sci. Med. 34: (1), 11-17.
27. Sulkes A, Beller U, **Peretz T**, Shacter J, Hornreich G, McDaniel C and Winograd B (1994). [Taxol: initial Israeli experience with a novel anticancer agent](#). Isr. J. Med. Sci. 30: (1), 70-78.
28. **Peretz T**, Baider L, Ever-Hadani P, Kaplan De-Nour A (1994). [Psychological distress in female cancer patients with holocaust experience](#). General Hospital Psychiatry. 16: 413-418.
29. Edelmann DZ, **Peretz T**, Barak V, Anteby SU (1995). [Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer](#). International Journal of Gynecological Cancer. 5: 443-448.

30. Shushan A, **Peretz T**, and Mor-Yosef A (1995). [A therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer: a preliminary report](#). Int J Gynecol Obstet. 52: 249-253.
31. Struewing JP, Abeliovich D, **Peretz T**, Avishai N, Kaback M.M, Collins F, and Brody L B (1995). [The carrier frequency of the BRCA1 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals](#). Nature Genetics. 11: 198-200.
32. Barak V, Livni N, **Peretz T**, Halperin T, Rosenmann E, Durst AL, and Roisman I (1995). [The role of CA 15-3 expression in serum and tissue of breast cancer patients](#). J Tumor Marker Oncology. 10: (3) 39-45.
33. Miao HQ, Ishai-Michaeli R, **Peretz T**, and Vlodayky I (1995). [Laminarin sulfate mimics the effects of heparin on smooth muscle cell proliferation and basic fibroblast growth factor receptor binding and mitogenic activity](#). J Cell Physiol. 164: 482-490.
34. Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O, Svahn CM, Ekre HP, Ishai-Michaeli R, Bar-Shavit R, Vlodayky I, and **Peretz T** (1995). [Structural requirements for inhibition of melanoma cell metastasis by heparanase inhibiting species of heparin](#). Isr. J. Med. Sci. 31: 106-118.
35. Vlodayky I, Miao HQ, Atzmon R, Levi E, Zimmermann J, Bar-Shavit R, **Peretz T**, and Ben-Sasson SA (1995). [Control of cell proliferation by heparan sulfate and heparin-binding growth factors](#). Thrombosis and Haemostasis. 74: 534-540.
36. Bar-Shavit R, Ginzburg Y, Maoz M, Vlodayky I, and **Peretz T** (1995). [The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site](#). Isr. J. Med. Sci. 31: 86-94.
37. Vlodayky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Wygoda MR, Ishai-Michaeli R, and **Peretz T** (1995). [Inhibition of tumor metastasis by heparanase-inhibiting species of heparin](#). Invasion and Metastasis. 14: 290-302.
38. Gorodetsky R, Mou X, Pfeffer MR, **Peretz T**, Levi Agababa F, and Wexler A (1995). [Subadditive effect of the combination of radiation and Cisplatin in cultured murine and human cell lines](#). Isr. J. Med. Sci. 31: 95-100.
39. Shushan A, Paltiel O, Iscovich J, Elchalal U, **Peretz T**, and Schenkar JG (1996). [Human menopausal gonadotropin and the risk of epithelial ovarian cancer](#). Fertil Steril. 65: 13-18.

40. Shushan A, **Peretz T**, Uziely B, Lewin A, and Mor-Yosef S (1996). [Ovarian cysts in premenopausal and postmenopausal tamoxifen treated women with breast cancer](#). Amer. J Obstet. and Gynecol. 174: 141-144.
41. Miao HQ, Ishai-Michaeli R, Atzmon R, **Peretz T**, and Vlodavsky I (1996). [Sulfate moieties in the subendothelial extracellular matrix are involved in basic fibroblast growth factor sequestration, dimerization and stimulation of cell proliferation](#). J Biol Chem. 271: (9) 4879-4886.
42. Sagi M, Heching NI, Kadouri L, Abeliovich D, Zlotogora J, Bach G, and **Peretz T** (1996). [Genetic Oncology Counseling - The Hadassah Experience](#). Harefuah. 130: (7) 441-446.
43. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, **Peretz T**, Ben-Neriah S, Yehuda O, and Rachmilewitz EA (1996). [Microsatellite instability and P53 mutations in therapy-related leukemia suggests mutator phenotype](#). Blood. 88: 4296-4303.
44. Lyass S, Lyass O, Gabizon A, **Peretz T**, Eid A, Muggia-Sullam M, Durst AL, and Shiloni E (1996). [Hepatic arterial bolus chemotherapy for colorectal metastases using an implantable port: a negative influence of previous systemic treatment](#). Int J Oncology. 9: 1295-1299.
45. Baider L, **Peretz T**, and Kaplan De-Nour A (1997). [The effect of behavioral intervention on the psychological distress of holocaust survivors with cancer](#). Psychotherapy and Psychosomatics. 66: 44-49.
46. Abeliovich D, Kadouri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching NI, and **Peretz T** (1997). [The founder mutation 185delAG and 5382insC in BRCA-1 and 6174delT in BRCA-2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women](#). Am J. Human Genetics. 60: 505-514.
47. **Peretz T**, Kaplan De-Nour A, Baider L, Hubert A, Stephanos S, Barak V (1997). [The combination of interferon and tamoxifen for patients with advanced breast cancer and negative estrogen receptors](#). The Breast. 6: (4) 190-193.
48. Metzger S, Goldschmidt N, Barash V, **Peretz T**, Drize O, Shilyansky J, Shiloni E, and Chajek-Shaul T (1997). [Interleukin-6 secretion in mice is associated with reduced glucose-6- phosphatase and liver glycogen levels](#). Am. J. Physiol. 273: E 262-267.
49. Nisman B, Lafair J, Heching NI, Lyass O, Baras M, **Peretz T**, Barak V (1998). [Evaluation of tissue polypeptide specific antigen CYFRA 21-1, and carcino-](#)

- [embryonic antigen in non small cell lung carcinoma](#). *Cancer*. 15: 82 (10) 1850-9.
50. Metzger S, Begleitbter N, Barash V, Drize O, **Peretz T**, Shiloni E, Chajek-Shaul T (1997). [Tumor necrosis factor inhibits the transcriptional rate of glucose-6-phosphatase in vivo and in vitro](#). *Metabolism*. 46: (5) 579-83.
 51. Barak V, Nisman B, Roisman I, Hubert A, Farbstein H, Kaplan A, Halperin T, Stephanos S, **Peretz T** (1997). [Tps in assessing response to therapy and prognosis of breast cancer patients treated with interferons](#). *J. Tumor Marker Oncology*. 12: (4) 17-26.
 52. Friedman E, Bar-Sade B, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, **Peretz T**, Lerer I, Weinberg N, Shushan A, and Abeliovich D (1998). [Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes](#). *Am J Hum Genet*. 63: (4) 1224-7.
 53. Barak V, Kalickman I, Nisman B, Farbstein H, Fridlender ZG, Baider L, Kaplan De-Nour A, Stephanos S, and **Peretz T** (1998). [Changes in cytokine production of breast cancer patients treated with interferons](#). *Cytokine*. 10: (12), 977-983.
 54. Sagi M, Kadouri L, Zlotogora J, and **Peretz T** (1998). [The effect of genetic counseling on knowledge and perceptions regarding risks for breast cancer](#). *Journal of Genetic Counseling*. 7: (5), 417.
 55. Lerer, I., Wang, T., Peretz, T., Sagi, M., Kaduri, L., Orr-Urtreger, A., Stadler, J., Gutman, H., & Abeliovich, D. (1998). [The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction](#). *American journal of human genetics*. 63(1), 272–274.
 56. Hubert A, **Peretz T**, Manor O, Kadouri L, Weinberg N, Lerer I, Sagi M, Abeliovich D (1999). [The Jewish Ashkenazi founder mutations in the BRCA1/2 genes are not found at an increased frequency in prostate cancer Ashkenazi patients](#). *Am J Human Genet*. 65: (3), 921-924.
 57. Kadouri L, Gips M, Hubert A, Sagi M, Heching N, Lerer I, Uziely B, Weinberg N, Abeliovich D, **Peretz T** (1999). [Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers](#). *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 85: 75-80.
 58. Nisman B, Amir G, Lafair J, Heching NI, Lyass O, **Peretz T**, Barak V (1999). [Prognostic value of Cyfra 21-1, TPS and CEA in different histologic types of non small cell lung cancer](#). *Anticancer Research*. 19: (4C) 3549-3552.

59. Baider L, **Peretz T**, Ever-Hadani P, Perry S, Avramov R, and Kaplan De-Nour A (2000). [Transmission of response to trauma? Second generation holocaust survivors' reaction to cancer](#). Am J Psychiatry. 157: (6) 904-910.
60. **Peretz T**, Weshler Z, Goldberg Y, Durst AL, Freund HR (2000). [Brief preoperative radiotherapy reduces local recurrences and improves survival in rectal cancer](#). Harefuah. 16: 138 (2), 96-99.
61. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, **Peretz T**, Pecker I, Pappo O (2000). [Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis](#). Am J Pathol. 157: (4) 1167-75.
62. Barak V, Nisman B, Hubert A, Lyass O, Kadouri L, **Peretz T** (2000). [Prognostic Efficacy of TPS in Breast Cancer](#). J Tumor Marker Oncology. 15: (3) 171-176.
63. Wang T, Lerer I, Gueta Z, Sagi M, Kadouri L, **Peretz T**, Abeliovich D (2001). [A deletion/insertion mutation in the BRCA1/2 gene in a breast cancer family: A possible role of the Alu-polyA tail in the evolution of the deletion genes](#). Genes, Chromosomes and Cancer. 31: 91-95.
64. Klein M, Weininger J, Moshe S, **Peretz T**, Chisin R (2001). [The use of external radioactive markers in scintimammography](#). Clinical Nuclear Medicine. 26: (1), 10-13.
65. Paltiel O, Avitzour T, **Peretz T**, Cherny N, Kadouri L, Pfeffer RM, Wagner N, Soskolne V (2001). [Determinants of the use of complementary therapies by cancer patients](#). Journal of Clinical Oncology. 19: (9), 2439-2448.
66. Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, **Peretz T**, Eeles RA (2001). [CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers](#). British Journal of Cancer. 85: (1), 36-40.
67. Manning AP, Abeliovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, **Peretz T**, Narod SA, Mes-Masson A.M, Foulkes WD, Wang T, Morgan K, Fujiwara TM, Tonin PN (2001). [Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families](#). Hum Hered. 52: (2), 116-120.
68. Baider L, **Peretz T**, Ever-Hadani P, Koch U (2001). [Psychological intervention in cancer patients: a randomized study](#). Gen Hosp Psychiatry. 23: (5) 272-277.

69. Tanos V, Brzezinsky A, Drize O, Strauss N, **Peretz T** (2002). [Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro](#). Eur J Obstet Gynecol Reprod Biol. 102: (2), 188-194.
70. Lotem M, **Peretz T**, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E (2002). [Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients \(AJCC stages III and IV\)](#). British Journal of Cancer. 20;86 (10): 1534-1539.
71. Nisman B, Barak V, Shapiro A, Golijanin D, **Peretz T**, Pode D(PI) (2002). [Evaluation of urine Cyfra 21-1 for the detection of primary and recurrent bladder carcinoma](#). Cancer. 94 (11) 2914-2922.
72. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, **Peretz T**, Yaron Y, Orr Urtreger A (2002). [A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, is Associated with Prostate Cancer in Ashkenazi Jews](#). Am J Hum Genet. 71(4); 981-4.
73. Ron IG, Wigler N, Borovik R, **Peretz T**, Rizel S, Shani A, Brenner J, Farbstein H, Brenner HJ, Chaïchik S, Catane R, Inbar MJ (2002). [CMF \(cyclophosphamide, methotrexate, 5-fluorouracil\) versus CNF \(cyclophosphamide, mitoxantrone, 5-fluorouracil\) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups](#). Am J Clin Oncol. 25(5):520-2.
74. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, **Peretz T** and Friedmann Y (2002). [Mamalian heparanase: involvement in cancer metastasis, angiogenesis and normal development](#). Cancer Biology. 12 (2): 121-129.
75. Nisman B, Barak V, Hubert A, Kadouri L, Lyass O, Baras M, **Peretz T** (2003). [Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy](#). Anticancer Research. 23: 1939-1942.
76. Lotem M, Anteby S, **Peretz T**, Ingber A, Avinoach I, Prus D (2003). [Mucosal melanoma of the female genital tract is a multifocal disorder](#). Gynecol Oncol. 88(1):45-50.
77. Richter ED, Friedman LS, Tamir Y, Berman T, Levy O, Westin JB, **Peretz T** (2003). [Cancer risks in naval divers with multiple exposures to carcinogens](#). Environ Health Perspect. 111(4):609-17.

78. Lotem M, Yehuda-Gafni O, Butnaryu E, Drize O, **Peretz T**, Abeliovich D (2003). [Cytogenetic analysis of melanoma cell lines. Subclone selection in long-term melanoma cell cultures.](#) Cancer Genet Cytogenet. 142(2):87-91.
79. Gronbaek H, Tanos V, Meirow D, **Peretz T**, Raz I, Flyvbjerg A (2003). [Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients.](#) Anticancer Res. 23 (3C): 2815-20.
80. Baider L, Ever-Hadani P, Goldzweig G, Wygoda MR, **Peretz T** (2003). [Is perceived family support a relevant variable in psychological distress? A sample of prostate and breast cancer couples.](#) J of Psychosomatic Res. 55: 453-460.
81. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, **Peretz T**, Gershoni R, Rizel S, Struewing JP, Modan B (2003). [Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel.](#) Gynecologic Oncol. 89: 494-498.
82. Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, **Peretz T**, Vlodavsky I, Kleinman HK (2003). [Regulation of heparanase gene expression by estrogen in breast cancer.](#) Cancer Res. 63, 8821-8826.
83. Shteper JP, Zcharia E, Ashhab Y, **Peretz T**, Vlodavsky I, Ben-Yehuda D (2003). [Role of promoter methylation in regulation of the mammalian heparanase gene.](#) Oncogene. 30:22 (49): 7737-49.
84. Kadouri L, Kote-Jarai S, Easton DF, Hubert A, Hamoudi R, Glaser B, Abeliovich D, **Peretz T**, Eeles RA (2004). [Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.](#) International J of Cancer. 20:108 (3): 399-403.
85. Lotem M, Drize O, Kadouri L, Weitzen R, Merims S, Shiloni E, Hamburger T, Frankenburg S, **Peretz T** (2003). [Interleukin-2 improves tumor response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.](#) British J of Cancer. 23:90(4) 773-80.
86. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, **Peretz T**, Mandelboim O, Ben-Yehuda D (2003). [Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma.](#) Cancer Res. 1; 63 (19). 6340-9.
87. Nissan A, Ram M, Spira MD, Hamburger T, Badriyah M, Prus D, Cohen T, Hubert A, Freund HR, **Peretz T** (2004). [Clinical profile of breast cancer in Arab and Jewish Women in the Jerusalem Area.](#) Am J of Surgery. 188(1):62-7

88. Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, Morag E, Bartfeld D, Lotem M, **Peretz T**, Pitcovski J (2004). [Production and purification of melanoma gp100 antigen and polyclonal antibodies](#). Protein Expression and Purification. 34(2):183-9.
89. Merimsky O, Gez E, Weitzen R, Nehushtan H, Rubinov R, Hayat H, **Peretz T**, Ben-Shachar M, Biran H, Katsenelson R, Mermershtein V, Loven D, Neumann A, Matcejevsky D, Inbar M (2004). [Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2](#). Ann Oncol. 15(4):610-2.
90. Frankenburg S, Elias O, Gelbart Y, Drize O, Lotem M, Ingber A, **Peretz T**, Pitcovski J (2004). [Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients](#). Immunol Letters. 15:94(3) 253-9.
91. Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, **Peretz T** (2004). [A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers](#). Br J Cancer. 17:90(10): 2002-5.
92. Edovitsky E, Elkin M, Zcharia E, **Peretz T**, Vlodayvsky I (2004). [Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis](#). J Natl Cancer Inst. 18:96(16):1219-30.
93. Paltiel O, Marzec-Boguslawska A, Soskolne V, Massalha S, Avitzour M, Pfeffer R, Cherny N, **Peretz T** (2004). [Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life](#). Quality of Life Research. 13 (10):1699-1706.
94. Stojadinovic A, Fields SI, Shriver CD, Lenington S, Ginor R, Peoples GE, Burch HB, **Peretz T**, Freund HR, Nissan A (2005). [Electrical impedance scanning of thyroid nodules before thyroid surgery: a prospective study](#). Ann Surg Oncol. 12(2):152-60.
95. Abboud-Jarrou G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, **Peretz T**, Vlodayvsky I (2005). [Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase](#). J Biol Chem. 8; 280(14):13568-75.
96. Galinsky D, Kisselgoff D, Sella T, **Peretz T**, Libson E, Sklair-Levy M (2005). [Effect of breast magnetic resonance imaging on the clinical management of breast cancer](#). Isr Med Assoc J. 7(11): 700-3.
97. Pitcovski J, Bazak Z, Wasserman E, Elias O, Levy A, **Peretz T**, Fingerut E, Frankenburg S (2006). [Heat labile enterotoxin of E. coli: a potential adjuvant for transcutaneous cancer immunotherapy](#). Vaccine. 30;24(5):636-43

98. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, **Peretz T**, Vlodavsky I, Abramovitch R (2006). [Heparanase promotes growth, angiogenesis and survival of primary breast tumors](#). Int J Cancer. 118(7):1609-17.
99. Nisman B, Heching N, Biran H, Barak V **Peretz T** (2006). [The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin releasing peptide and neuron-specific enolase in patients with advanced non-small cell lung cancer](#). Tumor Biology. 27(1):8-16.
100. Daum H, Sagi M, Pikarsky E, Pruss D, Hamburger T, **Peretz T** (2006). [Prophylactic oophorectomy among carriers of BRCA 1/2 mutations – demographic and pathologic data](#). Harefuah. 145 (1):13-17. (Hebrew).
101. Edovitsky E, Lerner I, Zcharia E, **Peretz T**, Vlodavsky I, Elkin M (2006). [Role of endothelial heparanase in delayed-type Hypersensitivity](#). Blood. 1;107(9):3609-16
102. Baider L, Goldzweig G, Ever-Hadani P, **Peretz T** (2006). [Psychological distress and coping in breast cancer patients and healthy women whose parents survived the Holocaust](#). Psychooncology. 15 (7):635-46.
103. Baraz L, Haupt Y, Elkin M, **Peretz T**, Vlodovsky I (2006). [Tumor suppressor p53 regulates heparanase gene expression](#). Oncogene. 29; 25(28):3939-47.
104. Grinbaum R, Nissan A, Beglaibter N, Cohen T, **Peretz T** (2006). [The prognostic value of CA 19-9 in the preoperative work-up of pancreatic cancer patients](#). Harefuah. 145(11): 793-4, 863.(Hebrew)
105. Kram V, **Peretz T**, Sagi M. (2006). [Acceptance of Preventatives Surgeries by Israeli Women Who had Undergone BRCA testing](#). Fam cancer. 5(4): 327-35.
106. Benhamron S, Nechushtan H, Verbovetski I, Krispin A, Abboud-Jarrous G, Zcharia E, Edovitsky E, Nahari E, **Peretz T**, Vlodavsky I, Mevorach D (2006). [Translocation of active heparanase to cell surface regulates degradation of extra cellular matrix cells](#). J Immunol. 1; 176 (11):6417-24.
107. Nissan A, Jager D, Roystacher M, Prus D, **Peretz T**, Eisenberg I, Freund HR, Scanlan M, Ritter G, Old LJ, Mitrani-Rosenbaum S (2006) [Mulimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients](#). Br J Cancer Mar. 13; 94 (5):681-5.
108. Kaduri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, **Peretz T** (2007). [Cancer risks in carriers of the BRACA 1/2 Ashkenazi founder mutations](#). J Med Genet. 16; 44(7):467-71.

109. Frankenburg S, Grinberg I, Bazak Z, Fingerut L, Pitcovski J, Gorodetsky R, **Peretz T**, Spira RM, Skornik Y, Goldstein RS. (2007). [Immunological activation following transcutaneous delivery of HR-gp100 protein](#). Vaccine. 6; 25(23):4564-70.
110. Stojadinovic A, Nissan A, Protic M, Adair CF, Prus D, Usaj S, Howard RS, Radovanovic D, Breberina M, Shriver CD, Grinbaum R, Nelson JM, Brown TA, Freund HR, Potter JF, **Peretz T**, Peoples GE (2007). [Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01](#). Ann Surg. 245(6):846-57.
111. Cohen I, Maly B, Simon I, Meirovitz A, Pikarsky E, Zcharia E, **Peretz T**, Vlodavsky I, Elkin M (2007). [Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer](#). Clin Cancer Res. 15; 13 (14):4069-77.
112. Baider L, Goldzweig G, Ever-Hadani P, **Peretz T** (2008). [Breast cancer and psychological distress: mothers' and daughters' traumatic experiences](#). Support Care Cancer. 16(4):407-414
113. Goldberg Y, Porat R, Sagi M, Eilat A, Kedar I, Shochat C, Mendelson S, Hamburger T, Nissan A, Hubert A, Shalev S, Bercovich D, Pikarski E, Lerer I, Abelovich D, **Peretz T** (2007). [A new oncogenetic service of counseling and diagnosing for hereditary non-polyposis colorectal cancer \(HNPCC\)](#) Harefuah. 146 (7):510-4,576,575.
114. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, **Peretz T**, Vlodavsky I, Elkin M (2008). [Function of Heparanase in Prostate Tumorigenesis: Potential for Therapy](#). Clin Cancer Res. 1;14(3):668-76.
115. Levy A, Pitcovski J, Elias O, Altuvia Y, Margalit H, **Peretz T**, Golenser J, Lotem M. (2008). [A melanoma multiepitope polypeptide induces specific CD8+ T cell response](#). Cellular Immunology. 250(1-2):24-30.
116. Shafat I, Pode D, **Peretz T**, Ilan N, Vlodavsky I, Nissman B. (2008). [Clinical significance of urine heparanase in bladder cancer progression](#). Neoplasia. 10 (2): 125-30.
117. Cohen T, Prus D, Shia J, Abu-Wasel B, Pinto MG, Freund HR, Stojadinovic A, Grakov A, **Peretz T**, Nissan A. (2008). [Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based](#). J Surg Oncol. 97(5):416-22.
118. Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, **Peretz T**, Lotem M. (2008) [Capture of tumor cell](#)

[membranes by trogocytosis facilitates detection and isolation of tumor-specific functional cytotoxic T lymphocytes](#). Cancer Res. 15; 68(6):2006-13.

119. Nisman B, Biran H, Heching N, Barak V, Ramu N, Nemirovsky I, **Peretz T** (2008). [Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival](#). Br J Cancer. 15;98(1):77-9
120. Goldberg YV, Porat RM, Kedar I, Shochat C, Sagi M, Eilat A, Mendelson S, Hamburger T, Nissan A, Hubert A, Kadouri L, Pikarski E, Lerrer I, Abeliovich D, Bercovich D and **Peretz T**. (2008) [Mutation spectrum in HNPCC in the Israeli population](#). Fam Cancer. 7(4):309-17.
121. Abboud-Jarrou GV, Atzmon R, **Peretz T**, Palermo C, Gadea BB, Joyca JA and Vlodavski I. (2008) [Cathepsin L is responsible for the processing and activation of proheparanase through multiple cleavages of a linker segment](#). J Biol Chem. 283(26):1:816708176.
122. Nissan A, Peoples GE, Abu-Waswl B, Adair CF, Prus D, Howard RS, Lenington SG, Fields SI, Freund HR, **Peretz T**, Burch HB, Shriver CD and Stojadinovich A (2008) [Prospective trial evaluating electrical impedance scanning of thyroid nodules before thyroidectomy: final results](#). Ann Surg. 247(5):843-853.
123. Kadouri L, Kote-Jarai Z, Baras M, Abeliovich D, Hamburger T, **Peretz T** and Eales RA (2008) [Glutathion-S-transferase M1, T1 and P1 polymorphisms and Breast Cancer risk in BRCA1/2 mutation carriers](#). Br J Cancer. 17; 98(12):2006-2010.
124. Katz D, Paltiel O, **Peretz T**, Revel A, Sharon N. Maly B, Michan N, Sklair-Levy M and Alweis T. (2008) [Beginning IVF treatment after age 30 increases the risk of breast cancer: results of a case control study](#). Breast J. 14(6):517-522.
125. Salah Z, Haupt S, Maoz M. Baraz L. Rotter V, **Peretz T**, Haupt Y and Bar-Shavit R. (2008) [P53 controls hPar1 function and expression](#) Oncogene. 20-27(54):6866-6874.
126. Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, **Peretz T** and Kadouri L. (2009) [Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer](#). Fam Cancer. 8(3):173-7.
127. Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, **Peretz T**, Lotem M. (2009) [Absence of founder BRCA1 and BRCA2 mutations in](#)

- [coetaneous malignant melanoma patients of Ashkenazi origin](#). Fam Cancer. 8(1):29-32
128. Toledano H, Goldberg Y, Kedar-Barnes I, Baris H, Porat RM, Shochat C, Bercovich D, Pikarsky E, Lerer I, Yaniv I, Abeliovich D, **Peretz T**. (2009) [Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I](#) Fam Cancer. 8(3):187-94.
 129. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, **Peretz T**, Vlodavsky I, Li JP. (2009) [Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases](#). PLoS ONE. 4(4):e5181.
 130. Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E, Siminovsky Y, Abeliovich D, **Peretz T**, Simon A, Laufer N (2009). [Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience](#). Prenat Diagn. 26;29(5):508-513
 131. Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, **Peretz T** (2009). [Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations](#). BMC Cancer 18:9:60.
 132. Nisman B, Yutkin V, **Peretz T**, Shapiro A, Barak V, Pode D (2009). [The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study](#). Anticancer Res. 29(10):4281-5.
 133. Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, **Peretz T** (2009). [Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells](#). Clin Cancer Res. 1; 15(15):4968-77.
 134. Ospovat I, Siegelmann-Danieli N, Grenader T, Hubert A, Hamburger T, **Peretz T**. (2009). [Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients](#). Tumori. 95(6):683-6.
 135. Nisman B, Biran H, Ramu N, Heching N, Barak V, **Peretz T** (2009). [The diagnostic and prognostic value of ProGRP in lung cancer](#). Anticancer Res. 29(11):4827-32.
 136. Rottenberg Y, Nisman B, **Peretz T** (2009). [Extreme high levels of CA19-9 associated with adenocarcinoma of the lung](#). Isr Med Assoc J. 11(2):116-7.

137. Rottenberg Y, Barchana M, Liphshitz I, **Peretz T** (2010). [The changing face of cancer in the elderly: only a demographic change?](#) Arch Gerontol Geriatr. 50(3):e59-62.
138. Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, **Peretz T**, Lotem M (2010). [Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.](#) Cell Immunol. 266(1):98-103.
139. Nisman B, Yutkin V, Nechushtan H, Gofrit ON, **Peretz T**, Gronowitz S, Pode D (2010). [Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.](#) Urology. 76(2):513.e1-6.
140. Meirovitz A, Kuten M, Billan S, Abdah-Bortnyak R, Sharon A, **Peretz T**, Sela M, Schaffer M, Barak V (2010). [Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer--a prospective pilot study.](#) Radiat Oncol. 25; 5:16.
141. Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T, Hubert A, Strul H, Kariiv R, Ben-Avi L, Savion M, Pikarsky E, Abeliovich D, Bercovich D, Lerer I, **Peretz T** (2010). [An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.](#) Fam Cancer. 9(2):141-50.
142. Nisman B, Allweiss T, Kaduri L, Maly B, Gronowitz S, Hamburger T, **Peretz T**. (2010). [Serum thymidine kinase 1 activity in breast cancer.](#) Cancer Biomark. 7(2):65-72
143. Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, **Peretz T**. (2011). [HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.](#) Tissue Antigens. 78 (3):203-7.
144. Lerner I, Hermano E, Zacharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y, Meirovitz A, **Peretz T**, Vlodaysky I, Elkin M. (2011) [Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice.](#) J Clin Invest. 121(5):1709-21.
145. Figer A, Nissan A, Shani A, Borovick R, Stiener M, Baras M, Freund HR, Sulkes A, Stojadinovic A, **Peretz T** (2011). [Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group \(ICOG\) Study.](#) J Cancer. 2:177-85.

146. Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, **Peretz T**, Elkin M (2011). [Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma](#). Cancer Res. 71(7) 2772-80.
147. Sonnenblick A, Appelbaum L, **Peretz T** (2011). [Liver failure on the background of pseudocirrhosis in patients with liver metastasis from breast cancer, who responded to treatment](#). Onkologie_34(4)199-201.
148. Sagi M, Eilat A, Ben Avi L, Goldberg Y, Bercovich D, Hamburger T, **Peretz T**, Lerer I. (2011). [Two BRCA1/2 founder mutations in Jews of Sephardic origin](#). Fam Cancer. 10(1):59-63.
149. Tahover E, Sonnenblick A, **Peretz T**, Katz D. (2012) [Update: adjuvant trastuzumab in HER-2 positive breast cancer](#). Harefuah. Jan; 151(1):37-42, 61. Review. Hebrew.
150. RZ Granit, Y Gabai, Y Karamansha, L Liberman, I Waldhorn, I Gat-Viks, A Regev, B Maly, M Darash-Yahana, **T Peretz** and Ben-Porat. (2012). [EZH2 promotes a bi-lineage identity in basal-like breast cancer cells](#). Oncogene. 15;32(33):3886-95.
151. Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, Yefenof E, **Peretz T**, Machlenkin A, Lotem M. (2012) [Trogoctysis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones](#). J Immunol;188(2):632-40.
152. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, **Peretz T**, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jaenne PA, Stephens PJ. (2012) [Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies](#). Nat Med.18(3):382-4.
153. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, Hamburger T, Mali B, **Peretz T**. (2012) [Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 \(tyrosine705-STAT3\) is a marker of good prognosis](#). Clin. Transl Oncology. 4(3); 232-6.
154. Lazar I, Perlman R, Lotem M, **Peretz T**, Ben-Yehuda D, Kadouri L. (2012) [The clinical effect of the inhibitor of apoptosis protein livin in melanoma](#). Oncology. 82(4):197-204

155. Salah Z, Uziely B, Jaber M, Maoz M, Cohen I, Hamburger T, Maly B, **Peretz T**, Bar-Shavit R. (2012) [Regulation of human protease-activated receptor 1\(hPar1\) gene expression in breast cancer by estrogen](#). FASEB J. 26(5):2031-42.
156. Slyper M, Shahar A, Bar-Ziv A, Granit RZ, Hamburger T, Maly B, **Peretz T**, Ben-Porath I. (2012) [Control of Breast Cancer Growth and Initiation by the Stem Cell-Associated Transcription Factor TCF3](#). Cancer Res. Nov 1; 72(21):5613-24.
157. Zcharia E, Atzmon R, Nagler A, Shimoni A, **Peretz T**, Vlodaysky I, Nagler A. (2012) [Inhibition of matrix metalloproteinase-2 by halofugionone is mediated by the Egr1 transcription factor](#). Anticancer drugs. Nov; 23(10):1022-31.
158. Sonnenblick A, Rottenberg Y, Kadouri L, Wygoda M, Rivkind A, Vainer GW, **Peretz T**, Hubert A. (2012) [Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer](#). Med. Oncol. Dec;29(5):3035-8
159. Sapoznik S, Faranesh S, Ortenberg R, Hamburger T, Barak V, **Peretz T**, Schachter J, Markel G, Lotem M. (2012), [Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients](#). Clin Dev Immunol. Epub Jan 16.
160. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, **Tamar P**, Jacob S, Gal M, Michal L. (2012) [Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients](#). Clin Dev Immunol. 2012:290536
161. Nisman B, Allweis T, Kadouri L, Mali B, Hamburger T, Baras M, Gronowitz S, **Peretz T**. (2012) [Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients](#). Clin Chem Lab Med. 51(2):439-47.
162. Nisman B, Maimon O, Allweis T, Kadouri L, Maly B, Hamburger T, **Peretz T**. (2013) [The prognostic significance of Liaison® CA15-3 assay in primary breast cancer](#). Anticancer Research. 33: 293-9.
163. Martine Klein, Michal M. Lotem, **Tamar Y. Peretz**, S. Tzila Zwas, S Mizrachi, Y Liberman, Roland Chisin, Jacob Schachter, Ilan G. Ron, Galina Yosilevsky, John A Kennedy, Ekaterina Revskaya, Annelies W de Kater, Eileen Banaga, Vicky Klutzaritz, Nadav Friedmann, E. Galun, Gerry DeNardo, Sally DeNardo, (2013), [Safety and efficacy of 1880Rhenium-labeled antibody to melanin in patients with metastatic melanoma](#). Journal of Skin Cancer. 828329.

164. Tahover E, Hubert A, Salah A, Temper M, **Peretz T**, Uziely B. (2013) [Hypertension as a predictive biomarker in bevacizumab treatment for cancer patients](#). Med Oncol. Mar; 30(1):327.
165. Haggi Mazeh, Itamar Sagiv, Daniela Katz, Herbert R. Freund, **Tamar Peretz**, and Tanir M. Allweis (2013) [Association between patient age, volume of breast tissue excised, and local recurrence](#). Journal of surgical research. 181;178-92
166. Katz D, Mazeh H, Meirovitz A, Uziely B, Rottenberg Y, Allweis TM, Revel A, **Peretz T**; (2013) [Women's post-chemotherapy parity is affected by offspring number and marital status](#). Breast. Jun;22(3):362-6
167. Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, **Peretz T**, Machlenkin A, Lotem M. (2013) [Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells](#); J Immunol. 190(11):5856-65
168. Yakir Rottenberg, Aviad Zick, Micha Barchana, **Tamar Peretz** (2013) [Organ specific cancer incidence in an industrial subdistrict: a population-based study with 12 years follow-up](#). American Journal of Cancer Epidemiology and Prevention. 1(1):2-10.
169. G. Goldzweig, S. Merims, R.Ganon, **T. Peretz**, A. Altman, L.Baider; (2013) [Informal caregiving to older cancer patients: Preliminary Research outcomes and implications](#). Annals of Oncology. 24(10):2635-40.
170. Luna Kadouri, Michal Sagi, Yael Goldberg, Israela Lerer, **Tamar Peretz**; (2013) [Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations](#); Brief Report, Breast Cancer Res Treat. June: 140:207-211.
171. Shmueli A, Fraifeld S, **Peretz T**, Gutfeld O, Gips M, Sosna J, Shaham D.; (2013); [Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience](#). Value Health. Sep-Oct; 16(6):922-31.
172. Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Simon Gronowitz, **Peretz T**; (2013), [Increased proliferative background in healthy women with BRCA ½ haploinsufficiency is associated with high risk for breast cancer](#); Cancer Epidemiology, Biomarkers & Prevention. 22:2110-2115.
173. Yael Goldberg, Inbal Kedar, Revital Kariiv , Naama Halper , Morasha Plesser, Ayala Hubert, Luna Kaduri, Michal Sagi , Israela Lerer , Dvorah Abeliovich, Tamar Hamburger, Aviram Nissan, Hanoch Goldshmidt, Irit Solar, Ravit Geva, Hana Strul, Guy Rosner, Hagit Baris, Zohar Levi, **Tamar Peretz**

- (2014); [Lynch Syndrome in High Risk Ashkenazi Jews in Israel](#) . Familial Cancer. 13(1):65-73.
174. Jaber M, Maoz M, Kancharia A, Agranovich D, **Peretz T**, Grisaru-Granovsky S, Uziely B, Bar-Shavit R; (2014) [Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer](#). Cellular and Molecular Life Sciences. 71:2517-2533.
175. Grenader T., Yerushalmi R., Tokar M., Fried G., Kaufman B., **Peretz T.**, Geffen D.; (2014) [The 21-gene recurrence score assay \(Oncotype DX\) in estrogen receptor positive male breast cancer: experience in an Israel cohort](#). Oncology; 87(1):1-6.
176. Braun M, Hasson-Ohayon I, Hales S, Zimmermann C, Rydall A, **Peretz T**, Rodin G; (2014) [Quality of Dying and Death with Cancer in Israel](#). Supportive Care in Cancer: 22(7):1973-1980.
177. Nechushtan H., Vainer G., Stainberg H., Salom A.Y., Hamburger T., Kadouri L., **Peretz T.**; (2014) [A phase ½ of a combination of Cetuximab and Taxane for “triple negative” breast cancer patients](#). The Breast: 23,4, 435-438.
178. Bar-Sela G., Keidar Z., **Peretz T.**, Ben-Itzhak O., Vornicova O., Hershkovitz D.; (2014) [Treatment of Metastatic extramammary Paget’s Disesae associated with Adnexal adenocarcinoma, with anti-Her2 durgs based on genomic alteration of Erbb2 S310f](#). The Oncologist. 19:1006-1007.
179. Nisman B., Nechushtan H., Biran H, Gantz-Sorotsky H., Peled N., Gronowitz S., **Peretz T.**: (2014) [Serum Thymidine Kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: A brief report](#). Journal of Thoracic Oncology. 9(10) 1568-1572.
180. Goldzweig G., Rotenberg Y., **Peretz T.**, Baider L.; (2014) [The silent partners: Formal caregivers of cancer patients and their oncologists](#). Annals of Oncology; Oct. 16.
181. Merimes S., Stivan F., **Peretz T.**, Lotem M.; (2014) [Melanoma in pregnancy: diagnostic and therapeutic challenges](#), ICJME. 3:149-52.
182. Hermano E., Meirovitz A., Meir K., Nummbaum G., Appelbaum L., **Peretz T.**, Elkin M.; (2014) [Macrophages are polarized by heparanase toward a tumor-promoting phenotype in pancreatic carcionoma](#). Journal of the National Cancer Institute. 18:106(12).
183. Nechushtan H., Hamamreh Y., Salim N., Gottfried M., Baron A, Israeli-Shalev Y, Nisman B, **Peretz T**, Peylan-Ramu N; (2015) [A Phase 2b trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non small cell lung cancer](#); The Oncologist 20(4)366-7.

184. G. Goldzweig, A. Abramovitch, B. Brenner, S. Perry, **T. Peretz**, L. Baider; (2014) [Expectatcions and level of satisfaction of patients and their physicians: Concordance and discrepencies](#). Psychosomatics. 15 (56) 521-529.
185. Goldberg Y, Barnes-Kedar I, Lerer I, Halpern N, Plesser M, Hubert A, Kadouri L, Goldshmidt H, Solar I, Strul H, Rosner G, Baris HN, **Peretz T**, Levi Z, Kariv R; (2015) [Genetic features of Lynch syndrome in the Israeli population](#). Clin Genet. 87(6)549-53.
186. Uzana R, Eisenberg G, Merims, Frankenburg S, Pato A, Yefenof E, Engelstein R, **Peretz T**, Machlenkin A, Lotem M.; (2015) [Human T cell crosstalk is induced by tumor membrane transfer](#). PLoS One. 11;10(2).
187. Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, Merims S, **Peretz T**, Lotem M, Gross G; (2015) [Messenger RNA encoding constitutively active toll-like receptor 4 enhances effector functions of human T cells](#). Clin Exp Immunol. 182(2): 220-229.
188. Jonathan E. Cohen, Yasmin Cohen, **Tamar Peretz**, Ayala Hubert; (2015) [Retrospective Study of the predictive value of target Now in systemic therapy for metastatic colorectal and gastric carcinomas](#). IMAJ. (17)612-615
189. Barak V, Meirovich A, Rachmut K, **Peretz T**, Elidan J, Gross m. (2015) [Diagnostic and prognostic value of tumor markers \(SCC, TPS, CYFRA 21-1, CEA\) in Head & Neck Cancer patients](#). Anticancer Res. 35(10):5519-24
190. Barak V, Leibovici V, Kalickman I, **Peretz T**, Lotem M, Merims S; (2015) [Assessing Response to new treatment and prognosis in Melanoma Patients, by the biomarker S-100b](#). Anticancer Research. 35(12)6755-6760.
191. Kancharla A, Maoz M, Jaber M, Agranovich D, **Peretz T**, Grisaru-Granovsky S, Uziely B1, Bar-Shavit R; (2015) [PH motifs in PAR1&2 endow breast cancer growth](#). Nature Communication. 6:8853
192. Zahavi T., Lanton T., Salmon Divon M., Salmon A., **Peretz T.**, Galun E., H. Axelrod J., Sonnenblick A.; (2015) [Sorafenib treatment during partial hepatectomy reduces tumorigenesis in an inflammation-assoicated liver cancer model](#); Oncotarget. (2016) 26;7(4) 4860-4870.
193. Zick A., Cohen S., Hamburger T., Goldberg Y., Zvi N., Sagi M and **Peretz T.**; (2015) [A BRCA1 Frame Shift Mutation in Women of Kurdish Jewish Descent](#); Open Medicine Journal. 2(1), 31–36.

194. **Peretz T.**, Paluch Shimon S., Soussan Gutman L, Kaplan Y, Dvir A., Barnes-Kedar I., Kadouri L, Semenisty V, Efrat N., Neiman V., Glasser Y, Michaelson-Cohen R., Katz L., Kaufman B., Golan T, Reish O, Hubert A, Safra T., Yaron Y. and Friedman E; (2016) [Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.](#) Breast cancer Res Treat. 155(1) 133-8
195. Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, **Peretz T**, Margalit A, Lotem M, Gross G (2016); [Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell adjuvants.](#) J Immunother. 39(2):60-70
196. Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar J, Onn A, Uziely B, **Peretz T**; (2016) [New ARCHITECT plasma-pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.](#) Breast Journal of Cancer. 16;114(4)469-76.
197. Orevi M, Freedman N, Tahover E, Uziely B, Chisin R, **Peretz T**, Klein M; (2016) [Is \(18\)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?](#) Acta Oncol. 55(2):244-7
198. Moshayoff V., Faktor O., Laghi L, Celesti G, **Peretz T.**, Keret D., Cohen D., Israeli E; (2016) [Feasibility of Unbiased RNA Profiling of Colorectal Tumors: A Proof of Principle](#) PLOS One. 21;11(7)
199. Gross M., Meirovich A., Rachmut J., **Peretz T.**, Eliashar R., Barak V.; (2016) [The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.](#) Anticancer research. 36(8) 4347-52.
200. Lotem M., Merims S., Frank S., Hamburger T., Nissan A., Kadouri L., Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B., Shneibaum S., Ozge Ayyildiz Z., Isbilen M., Mert Senses K., Ron I, Steinberg H., Smith Y., Shiloni E., Osmay Gure A., and **Peretz T.** (2016) [Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.](#) Journal of Immunology Research. Volume 2016, Article ID 8121985.
201. Rottenberg Y., Baider L, Jaccobs J.M., **Peretz T.**, Goldzweig G.; (2016) [Double Edged Sword: Women with breast cancer caring for a spouse with cancer:](#) Journal of Women's Health. 25; 12.

202. A. Zick, **T. Peretz**, M. Lotem, A. Hubert, D. Katz, M. Temper, Y. Rottenberg, B. Uziely, H. Nechushtan, A. Meirovitz, A. Sonnenblick, E. Sapir, D. Edelman, Y. Goldberg, A. Lossos, S. Rosenberg, I. Fried, R. Finklstain, E. Pikarsky, H. Goldshmidt; (2016), [Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients](#), *Medicine (Baltimore)*. 27(6)15-42.
203. Azraq Y., Eleyan F., Gill S., **Peretz T.**, Merimsky O. (2016) [Pazolimus: Pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis](#) *BMC Cancer*. 8;16:61.
204. Levin, N., Pato A., Cafri G., Eisenberg G., **Peretz T.**, Margalit A., Lotem M., Gross G. (2017) [Spontaneous activation of Antigen-presenting cells by genes encoding truncated Homo-oligomerizing derivatives of CD40](#). *J Immunother*. 40(2)39-50.
205. Zick A., Kadouri L., Cohen S., Frohlinger M., Hamburger T., Zvi N., Plaser M., Avital E., Breuier S., Elina F., Salah A., Goldberg Y., **Peretz T.** (2017) [Recurrent TP53 missense mutation in cancer patients of Arab descent](#). *Familial Cancer*. 16(2), 295-301.
206. Visochek L., Castiel A., Mittelman L., Elkin M., Atias D., Golan T., Izraeli S., **Peretz T.**, and Cohen-Armon M. (2017); [Exclusive destruction of mitotic spindles in human cancer cells](#) *Oncotarget*. 8(13)20813-20824.
207. Cohen J., Merims S., Frankl S., Engelstein R., **Peretz T.**, Lotem M. (2017) [Adoptive cell therapy: past, present and Future](#), *Immunotherapy*. 9(2), 183–196.
208. Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, **Peretz T**, Kadouri L (2017). [Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer](#). *Int J Cancer*. 140(9):2145- 214
209. Jaber M, Maoz M, Kancharla A, Agranovich D, **Peretz T**, Grisaru-Granovsky S, Uziely B, Bar-Shavit R (2017). [Erratum to: Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer](#). *Cell Mol Life Sci*. 2017;74(3):571-577.
210. Halpern N., Goldber Y., Kadouri L., Duvdevani M., Hamburger T., **Peretz T.**, Ayala Hubert (2017) [Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis](#). *OncoTargets and Therapy*. 10:1-8.

211. Zaidoun S., Uziely B., Jaber M., Maoz M., Cohen I., Hamburger T., Maly B., **Peretz T.**, Bar-Shavit R.:(2017) [Regulation of human protease-activated receptor 1 \(hPar1\) gene expression in breast cancer by estrogen](#) FASEB Journal. 26,(5) 2031-2042
212. Goldberg R., Sonnenblick A., Hermano E., Hamburger T., Meirovitz A., **Peretz T.** and Elkin M. (2017) [Heparanase augments insulin receptor signaling in breast carcinoma](#). Oncotarget. 8(12): 19403–19412.
213. Stemmer S., Steiner M., Rizel S., Geffen D., Nisenbaum B., **Peretz T.**, Soussan-Gutman L., et.al. (2017) [Clinical outcomes in ER+ Her2- Node-positive breast cancer patients who were treated according to the recurrence score results: Evidence from a large prospectively-design registry](#). NPJB Cancer. 8:3:32.
214. Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts BH, Pritchard CC, Tomlinson I, King MC, Levy-Lahad E, **Peretz T.**, Goldberg Y. (2017) [Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance](#). Gastroenterology. 152(8), 1876-1880.
215. A. Sonnenblick, R. Salgado, **T. Peretz**, P. Francis, J.P.A. Crown, E.D. Azambuja, A. Lieveke, M. Piccart2, J.F. Bromberg5, C. Sotiriou; (2018) [pSTAT3 in luminal breast cancer. Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial](#). International Journal of Oncology. 52(2): 424-432.
216. Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, **Peretz T.**, and Lotem M (2018) [Soluble SLAMF6 receptor induces strong CD8+ t-cell effector function and improves anti-melanoma activity in vivo](#). Cancer Immunology research. (6)2 127-138.
217. Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, **Peretz T.**, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russel K, Voss A, Dvir A, Soussan-Gutman L, Hubert A;(2018) [Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience](#). Targeted Oncology. 13(2): 217-226.
218. Rottenberg Y., Naeim A, Uziely B, **Peretz T.**, Jacobs JM; (2018) [Breast cancer among older women: The influence of age and cancer stage on survival](#). Archives of Gerontology and Geriatrics. 13(76); 60-64

219. Zahavi T, Sonnenblick A, Shimshon Y, Kaduri L, **Peretz T**, Salmon A. Y, Salmon-Divon M; (2018); [SYK expression levels distinguish control from BRCA1/2 mutated lymphocytes](#). Breast Cancer research and treatment. 10, 589-598.
220. Sonnenblick A, Salgado R, Brohée S, Zahavi T, **Peretz T**, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, De Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C. (2018) [p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial](#). Int J Oncol. 52(2):424-432.
221. Grinshpun A, Halpern N, Zvi Granit R, Hubert A, Hamburger T, Laitman Y, Shacham-Shmueli E, Peerless Y, Friedman E, **Peretz T** (2018) [Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers](#). European Journal of Human Genetics. 26(3)382–386.
222. Granit A, Tetro N.; Shmuel M.; **Peretz T.**; Eyal S.; (2018) [Lacosamide at therapeutic concentrations induces histonehyperacetylation in vitro](#). Epilepsy open. 30(4) : 535-539.
223. Barnes-Kedar, Bernstein-Molho R, Ginzach N1, Hartmajer S, Shapira T, Magal N, Kalis ML, **Peretz T**, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y. (2018) [The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations](#). Breast cancer Treatment & Research. 172, (1), 151–157.
224. Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, **Peretz T**, Lotem M, Gross G. (2018) [Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40](#). J Immunol. 15;201(10):2959-2968.
225. Granit RZ, Masury H, Condiotti R, Fixler Y, Gabai Y, Glikman T, Dalin S, Winter E, Nevo Y, Carmon E, Sella T, Sonnenblick A, **Peretz T**, Lehmann U, Paz K, Piccioni F, Regev A, Root DE, Ben-Porath I. (2018); [Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer](#). Cell Rep. 18;24(12):3237-3250.
226. Yanovich G, Agmon H, Harel M, Sonnenblick A, **Peretz T**, Geiger T.; (2018) [Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification](#). Cancer Res. 15;78(20):6001-6010
227. Cohen JE, Eleyan F, Zick A, **Peretz T**, Katz D. (2018); [Intratumoral immune-biomarkers and mismatch repair status in leiomyosarcoma -](#)

[potential predictive markers for adjuvant treatment: a pilot study.](#)
Oncotarget. 20;9(56):30847-30854

228. Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, **Peretz T**, Eisenberg G, Lotem M, Itzhaki O, Besser MJ, Gross G. [Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells.](#) J Immunother. 2019;42(2):43-50.
229. Grinshpun A, Gavert N, Granit RZ, Masuri H, Ben-Porath I, Breuer S, Zick A, Rosenberg S, Maoz M, Granit A, Pikarsky E, Strausman R, **Peretz T**, Sonnenblick A; (2018) [Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy.](#) Cancer Biol Ther.19(8):645-648
230. Kustanovich A, Schwartz R, **Peretz T**, Grinshpun A.(2019); [Life and death of circulating cell-free DNA.](#); Cancer Biol Ther. 16:1-11
231. Lieberman S, Beeri R, Walsh T, Schechter M, Keret D, Half E, Gulsuner S, Tomer A, Jacob H, Cohen S, Basel-Salmon L, Mansur M, Berger R, Katz LH, Golomb E, **Peretz T**, Levy Z, Kedar I, King MC, Levy-Lahad E, Goldberg Y (2019). [Variable Features of Juvenile Polyposis Syndrome With Gastric Involvement Among Patients With a Large Genomic Deletion of BMPR1A.](#) Clin Transl Gastroenterol.;10(7)
232. Bernstein-Molho R, Barnes-Kedar I, Ludman MD, Reznik G, Feldman HB, Samra NN, Eilat A, **Peretz T**, Peretz LP, Shapira T, Magal N, Kalis ML, Yerushalmi R, Vinkler C, Liberman S, Basel-Salmon L, Shohat M, Levy-Lahad E, Friedman E, Bazak L, Goldberg Y (2019). [The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients.](#) Breast Cancer Res Treat. 178(1):231-237.
233. Hermano E, Goldberg R, Rubinstein AM, Sonnenblick A, Maly B, Nahmias D, Li JP, Bakker MAH, van der Vlag J, Vlodaysky I, **Peretz T**, Elkin M (2019). [Heparanase Accelerates Obesity-Associated Breast Cancer Progression.](#) Cancer Res. 15;79(20):5342-5354.
234. Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, Yakobson A, Orevi M, Caplan N, **Peretz T**, Lotem M, Cohen JE (2020) [Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study.](#) Front Oncol.14;10:70.
235. Bernstein-Molho R, Friedman E, Kedar I, Laitman Y, Allweis TM, Gal-Yam EN, Feldman HB, Grinshpun A, Halpern N, Hartmajer S, Kadouri L, Katz LH, Kaufman B, Laish I, Levanon K, Philipsborn SL, Ludman

- M, Moran G, **Peretz T**, Reinstein E, Levi GR, Safra T, Shkedi S, Vinkler C, Levy Z, Goldberg Y(2020). [Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants](#). Breast Cancer Res Treat.;181(2):445-453.
236. Visochek L; Castiel A; Mittelman L; Elkin M; Atias D; Talia G; Izraeli S; **Peretz T**; Cohen-Armon M; (2020) [Correction: exclusive destruction of mitotic spindles in human cancer cells](#). Oncotarget 11(14) 1290-1291
237. Bar-Sela G, Samih Y, Yerushalmi R, Leviov M, Efrat Ben-Baruch N, Kuchuk I, Tokar M, **Peretz-Yablonski T**, Sonnenblick A, Soussan-Gutman L, Bareket-Samish A, Fried G, Paluch-Shimon S, Kaufman B, Hammerman A, Liebermann N, Stemmer SM (2020) [Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2-negative breast cancer patients in Israel: A registry analysis](#). Breast J. Oct;26(10):2096-2098.
238. Maeir T, Nahum M, Makranz C, Hoba A, **Peretz T**, Netanel Nagary S., Silberman N., Gilboa Y. (2020). [The feasibility of a combined model of online interventions for adults with cancer-related cognitive impairment](#). British Journal of Occupational Therapy. 80(11): 600-667.
239. Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, **Peretz T**, Shacham-Shmueli E (2020). [Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review](#). Onco Targets Ther. 13:11637-11644
240. Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, Eisenhaure T, Henrickson SE, Villani AC, Hacoheh N, Abudi N, Abramovich R, Cohen JE, **Peretz T**, Veillette A, Lotem M (2020). [SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint](#). Elife. 3(9) e52539.
241. Nisman B, Allweis TN, Carmon E, Kadouri L, Mali B, Maimon O, Meirovitz A and **Peretz T** (2021). [Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer](#). Anticancer Research. 41(2): 949-954.
242. Malishev R, Ben-Zichri S, Oren O, Shauloff N, **Peretz T**, Taube R, Papo N, Jelinek R. (2021). [The pro-apoptotic domain of BIM protein forms toxic amyloid fibrils](#). Cell Mol Life Sci. 78(5):2145-2155.

243. Kedar, I., Walsh, L., Levi, G. R., Lieberman, S., Shtaya, A. A., Nathan, S. N., Lagovsky, I., Tomashov-Matar, R., Goldenberg, M., Basel-Salmon, L., Katz, L., Aleme, O., **Peretz, T. Y.**, Hubert, A., Rothstein, D., Castellvi-Bel, S., Walsh, T., King, M. C., Pritchard, C. C., Levi, Z., ... Goldberg, Y. (2021). [A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer](#). Familial cancer, in press.
244. Sadeh R, Sharkia I, Fialkoff G, Rahat A, Gutin J, Chappleboim A, Nitzan M, Fox-Fisher I, Neiman D, Meler G, Kamari Z, Yaish D, **Peretz T**, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Maoz M, Abu-Gazala S, Ben Ya'acov A, Shteyer E, Safadi R, Kaplan T, Shemer R, Planer D, Galun E, Glaser B, Zick A, Dor Y, Friedman N. (2021). [ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin](#). Nat Biotechnol. 39(5):586-598.
245. Hajaj E, Zisman E, Tzaban S, Merims S, Cohen J, Klein S, Frankenburg S, Sade-Feldman M, Tabach Y, Yizhak K, Navon A, Stepensky P, Hacoheh N, **Peretz T**, Veillette A, Karni R, Eisenberg G, Lotem M. (2021). [Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T cell effector functions](#). Cancer Immunol Res. 9(6):637-650.
246. Shraga S, Grinshpun A, Zick A, Kadouri L, Cohen Y, Maimon O, Adler-Levy Y, Zeltzer G, Granit A, Maly B, Carmon E, Meiner V, Sella T, Hamburger T, **Peretz T**. (2021). [High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis](#). Front Oncol. 11:683656.
247. Miles D, Ciruelos E, Schneeweiss A, Puglisi F, **Peretz-Yablonski T**, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators (2021). [Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication](#). Ann Oncol. 32(10):1245-1255.
248. Meirovitz A, Nisman B, Allweis TM, Carmon E, Kadouri L, Maly B, Maimon O, **Peretz T**. (2022). [Thyroid Hormones and Morphological Features of Primary Breast Cancer](#). Anticancer Res. 42(1):253-261.

249. Lubotzky A, Zemmour H, Neiman D, Gotkine M, Loyfer N, Piyanzin S, Ochana BL, Lehmann-Werman R, Cohen D, Moss J, Magenheim J, Loftus MF, Brais L, Ng K, Mostoslavsky R, Wolpin BM, Zick A, Maoz M, Grinshpun A, Kustanovich A, Makranz C, Cohen JE, **Peretz T**, Hubert A, Temper M, Salah A, Avniel-Polak S, Grozinsky-Glasberg S, Spalding KL, Rokach A, Kaplan T, Glaser B, Shemer R, Dor Y. (2022). [Liquid biopsy reveals collateral tissue damage in cancer](#). *JCI Insight*. 25;7(2):e153559.
250. Grinshpun, A, Cohen Y, Zick A, Kadouri L, Hamburger T, Nisman B, Allweis TM, Oprea G, **Peretz T**, Uziely , and Sonnenblick A. (2022). [Potential Refinement of Recurrence Score by pSTAT3 Status](#). *Genes* 13, no. 3: 438.

Case Reports

1. **Peretz T**, Sulkes A, Polliack A, Weshler Z, Okon E, and Catane R (1985). [Secondary myelofibrosis with metastatic breast cancer](#). *Medical & Pediatric Oncology*. 13: 92-94.
2. **Peretz T**, Eliakim A, Goldin E, Isacson R, Biran S, and Durst AL (1987). [Duodenal ulcer complicating intraarterial chemotherapy by means of an implanted infusion pump](#). *Letter. Gastrointestinal Endoscopy*, 33: 127-128.
3. Margulies JY, Kenan S, Michowitz SD, Okon E, **Peretz T**, Matzner Y, and Floman Y (1987). [Cord compression as the presenting symptom of extradural malignant lymphoma](#). *Arch. Traumatic and Orthopedic Surgery*. 106: (5), 291-296.
4. Goldin E, Fich A, Libson E, and **Peretz T** (1988). [New endoscopic palliative treatments in gastrointestinal malignancies](#). *Isr. J. Med. Sci*. 24: 593-598.
5. Schuger L, **Peretz T**, Goldin E, Durst AL, and Okon E (1988). [Duodenal epithelial atypia. A specific complication of hepatic arterial infusion chemotherapy](#). *Cancer*. 61: 663-666.
6. Nori D, **Peretz T**, Exelby P, Ghavimi F, Mandell L, and Fuks Z (1989). [Sarcoma botryoides of the vagina: multimodel treatment](#). *ECHO*. 5: 142-150.
7. **Peretz T**, Ben-Yosef R, Lebensart P, Finkelstein R, Biran S, Durst AL, and Krausz M.M (1989). [Hepatic intra-arterial antibiotic therapy for resistant hepatic abscesses](#). *Int. Surg*. 74: 171-174.
8. Linares L, and **Peretz T** (1990). [Methemoglobinemia induced by topical anesthetic \(Benzocaine\)](#). *Radiotherapy and Oncology*. 1: 491-502.

9. Cass Y, Uziely B, Heching NI, Ramu N, Pappo Y, and **Peretz T** (1995). [A multiparous pregnant woman receiving chemotherapy for breast cancer: case report.](#) J of Oncology Pharmacy Practice. 1: (3) 37-39.
10. Lyass O, Brufman G, Edelmann DZ, Prus D, Lebensart PD, and **Peretz T** (1997). [Multiple parenchymal liver metastases as the first site of recurrent ovarian carcinoma: a case report and review of the literature.](#) European J. of Gynaecological Oncology. 18: (1) 68-70.
11. Leker RR, **Peretz T**, Hubert A, Lossos A (1997). [Vincristine induced paralytic ileus in Parkinson's disease.](#) Parkinsonism and Related Disorders. 3: 109-110.
12. Lyass O, Lossos A, Hubert A, Gips M, and **Peretz T** (1998). [Cisplatin induced non-convulsive encephalopathy.](#) Anticancer Drugs. 9: (1), 100-4.
13. Lotem M, Hubert A, Lyass O, Goldenhersh M.A, Ingber A, **Peretz T**, Gabizon A (2000). [Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.](#) Arch Dermatol. 136: (12), 1475-1480.
14. Peretz B, **Peretz T** (2003). [Chemotherapy for cancer in pregnant women: the effect on teeth of the offspring. Two case reports.](#) Pediatric Dentistry. 25(6):601-604.
15. Grenader T, Gutfeld O, Shavit L, Sella T, **Peretz T** (2006). [Metastatic testicular cancer presenting with venous thromboembolism.](#) Harefuah. 145(1):30-31. (Hebrew).
16. Grenader T, Shavit L, Ospovat I, Gutfeld O, **Peretz T** (2006). [Aortic occlusion in patients treated with Cisplatin-based chemotherapy.](#) Mt. Sinai J Med. Sept; 73(5):810-2.
17. Kaduri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G, Shochat C, Korem S, Hamburger T, Nissan A, Abu-Halaf N, Badriyah M, Abeliovich D, **Peretz T** (2007). [A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.](#) BMC Cancer. 18; 7:14.
18. Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, **Peretz T** (2007). [Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.](#) Clin Oncol (R Coll Radiol).19(7):490-3.
19. Katz D, **Peretz T**, Maly B, Ospovat I, Salim N, Ramu N, , Nechushtan H, Uziely B.(2008). [Expect the unexpected: Peritoneal spread- late relapse presentation of breast cancer.](#) Isr Med Assoc J. 10(4):310-1.
20. Rottenberg Y, Nisman B, **Peretz T**. (2009). [Extreme high levels of CA19-9 associated with adenocarcinoma of the lung.](#) Isr Med Assoc J. Feb;11(2):116-7

21. Sonnenblick A, Kadouri L, Appelbaum L, **Peretz T**, Sagi M, Goldberg Y, Hubert A. (2011). [Complete remission in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma treated with cisplatin based therapy](#). *Cancer Biol Ther.* 1;12(3):165-8.
22. Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, **Peretz T**, Hubert A. (2018) [Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report](#) *Mol Clin Oncol.* (5): 683–685

Letters

1. Shushan A, Abeliovich D, **Peretz T**, Weinberg N, Paltiel O (1997). [BRCA-1 mutations in women with ovarian cancer](#). (Letter); *JAMA.* 277: (12) 963.
2. Pikarski E, and **Peretz T** (2000). [Bone marrow metastases in breast cancer](#). *N Eng J Med.* 343: (8), 577-578. (Letter).
3. Spira RM, **Peretz T**, Hochner-Zelniker D and Freund HR (2001). [Levonorgestrel – releasing IUD and breast cancer](#). *Israel Medical Association Journal (IMAJ).* 3: 711-711. (Letter)
4. Richter ED, Friedman LS, Tamir Y, Berman T, Sadeh M, Levy O, Westin JB, **Peretz T**, Lipshitz I, Bar-Chana M (2003). *EHP* 111-12, 2003: [Correspondence](#). *Environ Health Perspect.* 111(12):A630-1.
5. Allweis, TM, Sagi, M, **Peretz, T** (2004). [Genetic counseling for women with breast cancer: the importance of evaluating the spouse](#). *Clin Genet.* Dec; 66(6): 573-4.
6. Grenader T, Shavit L, Uziely B, **Peretz T** (2005). [Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer](#). *J Natl Cancer Inst.* Feb 2;97(3):235-236.
7. Allweis TM, Sagi M, **Peretz T** (2005). [Sporadic breast cancer among relatives of BRCA mutation carriers](#). *Genet Med.* Nov-Dec; 7(9):655-6.
8. Orevi M, Freedman N, Tahover E, Uziely B, Chisin R, **Peretz T** and Klein M; (2015) [Is 18F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?](#) *Acta Oncologica.* Taylor Francis Online

Reviews, Commentaries, Hypotheses, Editorials

1. **Yablonski-Peretz T**, Catane R, Sulkes A, and Biran S (1984). [Small cell lung cancer](#). Harefuah. 106:450-453.
2. Sulkes A, **Peretz T**, Rizel S, Yahalom Y, and Biran S (1986). [New drugs in chemotherapy of malignant tumors: Cisplatin](#). Harefuah. 110: 90-92.
3. Goldin E, **Peretz T**, and Libson E: Giant duodenal ulcer (1988). [The hepatic intra-arterial chemotherapy IAHC variant](#). The Journal of Postgraduate Medicine. 64: 431-433.
4. Brzezinski A, **Peretz T**, Mor-Yosef S, and Schenker JG(1994). [Ovarian stimulation and breast cancer: is there a link?](#) Gynecological Oncology. 52: 292-295.
5. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Gera Ben-Dor C, Rabello E, Cass Y, **Peretz T**, Sulkes A, Chisin R, Barenholz Y (1994). [Clinical studies of liposome encapsulated doxorubicin](#). Acta Oncologica, 33: (7), 779-786.
6. Roisman I, **Peretz T**, Reznick AZ, Lifshitz I, Bitterman A, Fares F, Toledano H, Barzilai A, and Durst AL (1996). [Prognostic factors in breast cancer](#). Harefuah. 130: 693-698.
7. Roisman I, Barak V, Reznick A, Libson E, Bitterman A, **Peretz T**, and Durst AL (1996). [Breast cancer: screening detection, tumor markers and surgical management](#). J Tumor Marker Oncology. 11: 2.
8. Kadouri L, Sagi M, Heching NI, Abeliovich D, and **Peretz T** (1996). [The genetics of breast cancer](#). Harefuah. 131: 418-421.
9. Edelmann D Z, Anteby SU, and **Peretz T** (1996). [Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer](#). Harefuah. 131: 31-36.
10. Hochner-Celnikier D, Anteby SU, Shimonovitz S, Vromen A, **Peretz T**, and Yagel S (1996). [Gynecologic side effects of tamoxifen therapy for breast cancer: proposal for follow-up and treatment: Israel](#). J of Obstet Gynecol. 7: (3) 117-124.
11. Zlotogorsky A, and **Peretz T** (1997). [Molecular biology of melanoma](#). Harefuah. 132: 11.
12. Vlodaysky I, Miao HQ, Benezra M, Lider O, Bar-Shavit R, Schmidt A, and **Peretz T** (1997). [Involvement of the extracellular matrix, heparan sulphate proteoglycans, and heparan sulphate degrading enzymes in angiogenesis and metastasis](#). Tumor Angiogenesis. 125-140.

13. Lotem M, Shiloni E, Ingber A, and **Peretz T** (1997). [Active immunotherapy in malignant melanoma](#). Harefuah. 133: (3-4) 122-26.
14. Zcharia E, Metzger S, Chajek-Shaul T, Friedmann Y, Pappo O, Aviv A, Elkin M, Pecker I, **Peretz T**, and Vlodavsky I (2001). [Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis](#). J Mammary Gland Biol Neoplasia. 6: (3) 311-322.
15. Vlodavsky I, Goldschmidt O, Zcharia E, Metzger S, **Peretz T**, Pecker I, and Friedmann Y (2001). [Molecular properties and involvement of heparanase in cancer progression and normal development](#). Biochimie. 83: 831-839.
16. Vlodavsky I, Goldschmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, **Peretz T**, Friedmann Y (2002). [Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development](#). Seminars in Cancer Biology. 12, 121-129.
17. Barak V, Nisman B, Hubert A, Lyass O, **Peretz T** (2002). [Cytokeratins: Clinical utility in breast cancer](#). Journal of Clinical Ligand Assay. 25 (1).
18. Nechushtan H, **Peretz T** (2002). [Tamoxifen and breast cancer](#). Harefuah, 141(8):718-20, 761, 760.
19. Allweis TM, Nissan A, Spira RM, Sklair-Levy M, Freund HR, **Peretz T** (2003) [Screening mammography for early diagnosis of breast cancer: facts, controversies, and the implementation in Israel](#). Harefuah. 142(4):281-6, 317.
20. Yin, YJ, Salah Z, Grisaru-Granovsky S, Cohen I, Cohen-Even Ram S, Maoz M, Uziely B, **Peretz T**, Bar-Shavit R (2003). [Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness](#). Arterioscl Thromb Vasc Biol. 23: 940-944.
21. Grenader T, **Peretz T**, Lifchitz M, Shavit L (2005). [BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use](#). Breast. Aug;14(4):264-8.
22. Rottenberg Y, Barchana M, Liphshitz I, **Peretz T**. (2010). [The changing face of cancer in the elderly: only a demographic change?](#) Arch Gerontol Geriatr. 50(3):e59-62.

Multi-center studies

1. Van Dalen A, Heering KJ, Barak V, **Peretz T**, Cremaschi A, Geroni P, Gion M, Saracchini S, Molina R, Namer M, Stieber P, Sturgeon C, Leonard RCF, and Einarsson R (1996). [Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes.](#) The Breast. 5: 82-88.
2. Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, Renard H, KConFab Consortium, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, **Peretz T**, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olah E, Bignon YJ, Ruiz P, Badzioch MD, Vasen HF, Futreal AP, Phelan CM, Narod SA, Lynch HT, Ponder BA, Eeles RA, Meijers-Heijboer H, Stoppa-Lyonnet D, Couch FJ, Eccles DM, Evans DG, Chang-Claude J, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE, Stratton MR (2002). [From the Cover: Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.](#) Proc Natl Acad Sci USA. 22;99(2):827-831.
3. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, **Peretz T**, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR (2002). [Low-penetrance susceptibility to breast cancer due to CHEK2\(*\)1100delC in non-carriers of BRCA1 or BRCA2 mutations.](#) Nat Genet. 31(1):55-9.
4. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; **IMpassion131 investigators** (2021). [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.](#) Ann Oncol. 32(8):994-1004.
5. Lerner-Geva L, Chetrit A, Farhi A, Lubin F, Sadezki S; **National Israel Ovarian Cancer Study Group** (2022). [Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer.](#) Arch Gynecol Obstet. In press.